NEAT 022 (SSAT060)

 

An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppression

 

Phase: IV

 

Indication: HIV-1 patients on PI/r plus two NRTIs

 

Countries:  UK, France, Germany, Belgium, Spain, Italy

 

Status: Closed

Administrative office: NEAT ID Foundation, 27 Old Gloucester Street, London WC1N 3AX, UK

     e: NEAT-ID@NEAT-ID.org     

w: www.NEAT-ID.org

Registered address: PL 709  Rue Haute 322, 1000 Brussels, Belgium

©NEAT ID 2019